Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference

EAST NORRITON, Pa., Sept. 7, 2011 /PRNewswire/ -- Tengion, Inc (NASDAQ: TNGN), a leader in regenerative medicine, today announced that Brian Davis, Vice President and Chief Financial Officer of Tengion, will present at the upcoming Rodman & Renshaw 13th Annual Healthcare Conference on Tuesday, September 13, 2011, at 1:35 pm EDT.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com or by accessing http://www.wsw.com/webcast/rrshq20/tngn  . Investors interested in listening to the live webcast should log on before the start time in order to download any required software.  This webcast will also be archived.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

SOURCE Tengion, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.